Connor, Clark & Lunn Investment Management Ltd. Protalix Bio Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

  • $21.8 Billion
  • Q1 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024
SELL
$1.34 - $1.85 $129,371 - $178,610
-96,546 Reduced 57.63%
70,990 $126,000
Q3 2023

Nov 13, 2023
BUY
$1.49 - $2.02 $77,475 - $105,033
51,997 Added 45.0%
167,536 $278,000
Q2 2023

Aug 10, 2023
SELL
$2.0 - $3.36 $86,328 - $145,031
-43,164 Reduced 27.2%
115,539 $231,000
Q1 2023

May 09, 2023
BUY
$1.37 - $2.16 $217,423 - $342,798
158,703 New
158,703 $333,000

Others Institutions Holding PLX

# of Institutions
66
Shares Held
9.27M
Call Options Held
40.6K
Put Options Held
10.1K
View Full List

About Protalix BioTherapeutics, Inc.

PLX Quotes by TradingView
  • Ticker PLX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,753,400
  • Market Cap $53.7M
  • Description
  • Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...
More about PLX
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email